Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 1, 2024Research and Practice in Thrombosis and HaemostasisOpen Access

Caplacizumab improves clinical outcomes and is well tolerated across clinically relevant subgroups of patients with immune-mediated thrombotic thrombocytopenic purpura

View Full Paper
Ask AI
Bookmark
Share

Authors

KPKaterina PavenskiSt. Michael's HospitalMSMarie ScullyUniversity College HospitalPCPaul CoppoDélégation Paris 5

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Pavenski et al. (2024) studied this question.

synapsesocial.com/papers/68e62074b6db6435875b21aahttps://doi.org/10.1016/j.rpth.2024.102512
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Should we consider caplacizumab as routine treatment for acute thrombotic thrombocytopenic purpura? An expert perspective on the pros and cons2024 · 5 citations
  2. 2IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA: PATHOPHYSIOLOGY, DIAGNOSIS AND OPEN ISSUES.2024 · 5 citations
  3. 3Tailoring Caplacizumab Administration Using ADAMTS13 Activity for Immune-mediated Thrombotic Thrombocytopenic Purpura2024 · 3 citations
  4. 4Real-World Data Analysis of Patients Affected by Immune-Mediated Thrombotic Thrombocytopenic Purpura in Italy2024 · 2 citations
  5. 5#1491 Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange2024 · 1 citations